Printed From BioPortfolio.com
FDA approves Xcision’s GammaPod stereotactic radiotherapy system for breast cancer
04:34 EST 10 Jan 2018 | Medical Business Review
Xcision Medical Systems has secured 510(k) clearance from the US Food and Drug Administration (FDA) for the GammaPod stereotactic radiotherapy system, the world's first noninvasive external beam system optimized for partial breast treatments.
Original Article: FDA approves Xcision’s GammaPod stereotactic radiotherapy system for breast cancer
